Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study

Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease

(2018) L.M. Bekris et al.   JOURNAL OF NEUROIMMUNOLOGY

Triggering Receptor Expressed on Myeloid Cells 2 Deficiency Alters Acute Macrophage Distribution and Improves Recovery after Traumatic Brain Injury

(2017) Maha Saber et al.   JOURNAL OF NEUROTRAUMA

Trends in dementia prevalence, incidence, and survival rate in a Japanese community

(2017) Tomoyuki Ohara et al.   NEUROLOGY

Elucidating the Role of TREM2 in Alzheimer’s Disease

(2017) Jason D. Ulrich et al.   NEURON

Increased expression of triggering receptor expressed on myeloid cells-1 in the population with obesity and insulin resistance

(2017) Saravanan Subramanian et al.   Obesity

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

(2016) Laura Piccio et al.   ACTA NEUROPATHOLOGICA

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

(2016) Xianyuan Xiang et al.   EMBO Molecular Medicine

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

(2016) Marc Suárez‐Calvet et al.   EMBO Molecular Medicine

Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease

(2016) Taylor R. Jay et al.   JOURNAL OF NEUROSCIENCE

TREM2/DAP12 Signal Elicits Proinflammatory Response in Microglia and Exacerbates Neuropathic Pain

(2016) M. Kobayashi et al.   JOURNAL OF NEUROSCIENCE

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

(2016) Amanda Heslegrave et al.   Molecular Neurodegeneration

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

(2016) Annika Öhrfelt et al.   Multiple Sclerosis Journal

TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy

(2016) Peng Yuan et al.   NEURON

Early changes in CSF sTREM2 in dominantly inherited Alzheimers disease occur after amyloid deposition and neuronal injury

(2016) M. Suarez-Calvet et al.   Science Translational Medicine

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

(2016) Kristi Henjum et al.   Alzheimers Research & Therapy

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

(2016) Annika Öhrfelt et al.   Multiple Sclerosis Journal

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

(2015) Christina M. Lill et al.   Alzheimers & Dementia

TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model

(2015) Yaming Wang et al.   CELL

TREM2 deficiency eliminates TREM2+inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

(2015) Taylor R. Jay et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Midlife and Late-Life Smoking and Risk of Dementia in the Community: The Hisayama Study

(2015) Tomoyuki Ohara et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains

(2015) Caihong Zhu et al.   NEUROBIOLOGY OF AGING

TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis

(2014) G. Kleinberger et al.   Science Translational Medicine

The impact of microglial activation on blood-brain barrier in brain diseases

(2014) Anna Carolina Carvalho da Fonseca et al.   Frontiers in Cellular Neuroscience

TREM2 and the neuroimmunology of Alzheimer's disease

(2013) Suzanne E. Hickman et al.   BIOCHEMICAL PHARMACOLOGY

TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease

(2013) Sruti Rayaprolu et al.   Molecular Neurodegeneration

Heterozygous TREM2 mutations in frontotemporal dementia

(2013) Barbara Borroni et al.   NEUROBIOLOGY OF AGING

Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia

(2013) Elise Cuyvers et al.   NEUROBIOLOGY OF AGING

Neuroinflammation: The role and consequences

(2013) Monty Lyman et al.   NEUROSCIENCE RESEARCH

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

(2012) Thorlakur Jonsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose tolerance status and risk of dementia in the community: The Hisayama Study

(2011) T. Ohara et al.   NEUROLOGY

Criteria for Evaluation of Novel Markers of Cardiovascular Risk

(2009) Mark A. Hlatky et al.   CIRCULATION

High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese

(2008) Hisatomi Arima et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation

(2008) Laura Piccio et al.   BRAIN

Clinicopathological Outline of Dementia with Lewy Bodies Applying the Revised Criteria: The Hisayama Study

(2008) Kouhei Fujimi et al.   BRAIN PATHOLOGY